Alphaiota and PMcardio announce the expansion of their strategic partnership to bring the first AI-powered heart attack diagnostic solution to the Kingdom of Saudi Arabia. Developed by Powerful Medical, a medical device manufacturer specializing in AI-driven cardiovascular diagnostics, PMcardio will be introduced by Alphaiota as the exclusive distributor in the region, marking a first-of-its-kind deployment in the Middle East.
As a leading force in AI across the Kingdom and wider region, particularly in the healthcare sector, Alphaiota is working to localize and deploy world-class technologies that align with Saudi Arabia’s national vision for digital health. This partnership leverages the strengths of both organizations to address critical gaps in cardiac care.
Early diagnosis remains a critical challenge in improving outcomes for heart attack patients. “Heart attacks are still killing millions every year—not because we lack the tools to treat them, but because we often fail to diagnose them fast enough. With PMcardio, we’re changing that,” said Martin Herman, CEO and Co-Founder of Powerful Medical. “Our partnership with Alphaiota brings this life-saving technology to one of the most visionary healthcare markets in the world. Saudi Arabia’s commitment to medical excellence and innovation makes it the ideal environment for transforming acute cardiac care through AI.”
PMcardio addresses one of the most pressing challenges in cardiac care: the early and accurate diagnosis of high-risk chest pain patients. Clinically validated to detect 39 cardiac conditions from a standard 12-lead ECG, PMcardio identifies acute heart attacks up to three hours earlier and with twice the sensitivity of the current standard of care. The platform supports faster triage and quicker intervention in emergency settings, with the clear goal of improving outcomes for cardiovascular patients.
PMcardio is already trusted by over 100,000 healthcare professionals and has been used to screen more than 1.35 million patients worldwide. Backed by more than 30 published clinical studies and a global network of 40+ research institutions, the technology was recently recognized by Google for Startups: AI for Health 2024 as one of the top AI solutions in healthcare.
“The partnership with PMcardio exemplifies our commitment to deploying world-class AI solutions that are tailored to the Kingdom’s needs. By aligning technology with local priorities, we are contributing to Saudi Arabia’s broader Vision 2030, accelerating digital transformation, enhancing service delivery, and building national capabilities where they matter most,” said Thamir Alballaa, CEO of Alphaiota.
This launch represents a key milestone in Alphaiota’s mission to deploy localized, cutting-edge AI solutions that improve outcomes across sectors, including healthcare. By introducing PMcardio to the Kingdom, Alphaiota is helping position Saudi Arabia as a leading regional hub for healthcare innovation.
